Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study - PubMed (original) (raw)

. 2008 Sep;134(9):1037-42.

doi: 10.1007/s00432-008-0361-y. Epub 2008 Feb 9.

Joseph Skarda, Jiri Ehrmann, Paul G Murray, Eduard Fridman, Jury Kopolovic, Petra Knizetova, Marian Hajduch, Jiri Klein, Vitezslav Kolek, Lenka Radova, Zdenek Kolar

Affiliations

Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study

Katerina Vrzalikova et al. J Cancer Res Clin Oncol. 2008 Sep.

Abstract

Purpose: Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes.

Methods: Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS.

Results: Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05).

Conclusions: Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Immunohistochemical staining of Bmi-1 in a lymphocytes, b bronchial glands, c normal bronchial epithelium, d squamous cell carcinoma, e adenocarcinoma, f large cell carcinoma

Fig. 2

Fig. 2

Expression of Bmi-1 in different stages of NSCLC

Fig. 3

Fig. 3

Expression of Bmi-1 in different histological subtypes of NSCLC

Fig. 4

Fig. 4

DFS of stage I and II patients related to Bmi-1 expression and adjuvant chemotherapy

References

    1. Bea S, Tort F, Pinyol M et al (2001) BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61:2409–2412 - PubMed
    1. Breuer RH, Snijders PJ, Smit EF et al (2004) Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6:736–743 - DOI - PMC - PubMed
    1. Breuer RH, Snijders PJ, Sutedja GT et al (2005) Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 48:299–306 - DOI - PubMed
    1. Broers JL, Viallet J, Jensen SM et al (1993) Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am J Respir Cell Mol Biol 9:33–43 - PubMed
    1. Bruggeman SW, Valk-Lingbeek ME, van der Stoop PP et al (2005) Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 19:1438–1443 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources